Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) — Obagi Medical, a number one innovator in physician-dispensed skincare and aesthetic options and a part of Waldencast plc (NASDAQ: WALD), at this time introduced new knowledge shared on the latest American Society for Dermatologic Surgical procedure (ASDS) Annual Assembly, which befell November 13–16, 2025, in Chicago, Illinois.

Pivotal FDA Research Comparability of Two Hyaluronic Acid Fillers for Midface Augmentation and Related Enchancment in Nasolabial Folds Look led to Obagi Hyaluronic Acid Featured as a Prime 10 Summary Offered by Dr. Sue Ellen Cox:

“As an investigator on this pivotal research, I used to be happy that the information was acknowledged as one of many prime 10 abstracts and chosen for an oral presentation,” commented Dr. Sue Ellen Cox. “The information highlights the compelling outcomes of the Obagi^® saypha^® ChIQ™ pivotal research and exhibits the potential of the product to supply high-level satisfaction for sufferers in search of long-lasting, natural-looking outcomes.”

This pivotal, randomized, multicenter trial in contrast the effectiveness and security of two hyaluronic acid fillers for midface quantity restoration and nasolabial fold enchancment. The research demonstrated non-inferiority of Obagi® saypha® ChIQ™ ** in comparison with Juvéderm Voluma® XC, with excessive affected person satisfaction and sturdy security throughout numerous pores and skin varieties.

Extra Abstracts:

Obagi Scalp Serum Interim 3 Month Outcomes

Interim knowledge from the continuing research of Obagi Nu-Cil® BioStim™ Scalp Serum highlights enhancements in scalp well being and hair look at three months.

A Scientific Framework for Evaluating Hyaluronic Acid Filler Crosslinking Applied sciences

This analysis introduces a novel framework for evaluating HA fillers and showcases category-leading capabilities of the Obagi line of injectables.

“Obagi Medical’s dedication to advancing dermatologic science and driving innovation is mirrored within the knowledge shared throughout our skincare and injectable portfolio on the latest ASDS assembly,” mentioned Drew Superb, U.S. Basic Supervisor, Skilled Channel. “New merchandise with confirmed high quality, a well-established security profile, and excessive affected person satisfaction are vital to increasing the aesthetic injectable market. The number of the Obagi® saypha® ChIQ™ summary as one of many prime 10 for oral presentation highlights the highly effective knowledge supporting the brand new Obagi injectable.”

Nu-Cil® BioStim™ Scalp Serum expands on Obagi’s 35 years of pores and skin well being experience and management in medical-grade innovation by making use of its skin-first philosophy to the scalp via the BioStim™ Complicated. The BioStim™ Complicated makes use of proprietary expertise powered by a synergistic mix of clinically confirmed actives, together with biotin, amino acids, and peptides—alongside 18 important vitamins, B nutritional vitamins, and phytoactives. These actives work to advertise scalp well being, fortify hair follicles, and strengthen strands from the foundation.

Obagi® saypha® ChIQ™, developed by Croma-Pharma GmbH, makes use of proprietary MACRO Core Expertise that creates a steady 3D HA matrix designed to supply natural-looking outcomes with category-leading capabilities, together with excessive HA content material upon injection, constant gel distribution, and a predictable injection drive and swelling profile. Obagi® saypha® ChIQ™ is at present below overview for FDA approval. Obagi Medical’s Obagi® saypha® MagIQ™ was not too long ago FDA accredited.

About Obagi Medical
Obagi Medical is an industry-leading, superior skincare line rooted in analysis and pores and skin biology, with a legacy of 35+ years of expertise. Initially identified for its management within the therapy of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical merchandise are designed to deal with a wide range of pores and skin issues, together with untimely growing older, photodamage, pores and skin discoloration, zits, and solar harm. Because the fastest-growing skilled skincare model within the U.S. in 2024,* Obagi Medical empowers people to realize wholesome, stunning pores and skin. Extra details about Obagi is out there on the model’s web site, https://www.obagi.com.

*Among the many Prime 10 Skilled Pores and skin Care Manufacturers within the U.S., Based on Kline’s 2024 International Skilled Pores and skin Care Collection (China, Europe and the U.S.)
** Obagi® saypha® ChIQ™ is at present below overview for FDA approval

About Waldencast
Based by Michel Brousset and Hind Sebti, Waldencast’s ambition is to construct a worldwide best-in-class magnificence and wellness working platform by growing, buying, accelerating, and scaling aware, high-growth purpose-driven manufacturers. Waldencast’s imaginative and prescient is basically underpinned by its brand-led enterprise mannequin that ensures proximity to its prospects, enterprise agility, and market responsiveness, whereas sustaining every model’s distinct DNA. Step one in realizing its imaginative and prescient was the enterprise mixture with Obagi Medical and Milk Make-up. As a part of the Waldencast platform, its manufacturers will profit from the operational scale of a multi-brand platform; the experience in managing world magnificence manufacturers at scale; a balanced portfolio to mitigate class fluctuations; asset gentle effectivity; and the market responsiveness and pace of entrepreneurial indie manufacturers. For extra info please go to: https://ir.waldencast.com/. 

About Croma-Pharma GmbH 
Based in 1976, Croma-Pharma GmbH is a family-owned world participant within the area of minimally invasive aesthetic drugs. Headquartered in Leobendorf, Austria, the corporate specializes within the industrial manufacturing of hyaluronic acid syringes and distributes its merchandise in additional than 80 nations. Croma affords a complete aesthetics portfolio together with HA fillers, botulinum toxin, PDO threads, and biostimulators. Saypha(R) is a registered trademark of Croma-Pharma GmbH, used below license. Study extra at http://www.croma.at. 

Ahead-Wanting Statements
This press launch incorporates sure forward-looking statements inside the which means of the federal securities legal guidelines, together with statements concerning the deliberate launch of Saypha® MagIQ™, the flexibility to acquire FDA approval for Saypha®, and the expansion methods of Waldencast, together with Obagi Medical and Novaestiq. These forward-looking statements usually are recognized by the phrases “estimates,” “tasks,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “might,” “will,” “would,” “ought to,” “future,” “suggest,” “goal,” “objective,” “goal,” “outlook” and variations of those phrases or related expressions (or the adverse variations of such phrases or expressions) are supposed to determine forward-looking statements. These forward-looking statements should not ensures of future efficiency, circumstances or outcomes, and contain various identified and unknown dangers, uncertainties, assumptions and different vital components, a lot of that are outdoors the management of Waldencast, Obagi Medical and Novaestiq that might trigger precise outcomes or outcomes to vary materially from these mentioned within the forward-looking statements. Essential components, amongst others, that will have an effect on precise outcomes or outcomes embrace, however should not restricted to: (i) the shortcoming to acquire FDA approval for Saypha® ChIQ merchandise, (ii) the success of any business launches, (iii) the overall impression of geopolitical occasions, together with the impression of present wars, conflicts and different hostilities, (iv) the general financial and market circumstances, gross sales forecasts and different details about Waldencast’s potential or assumed future outcomes of operations or our efficiency, (v) adjustments on the whole financial circumstances, (vi) the impression of any worldwide commerce or overseas change restrictions, the imposition of latest or elevated tariffs, overseas forex change fluctuations, (vii) that the value of Waldencast’s securities could also be unstable as a result of a wide range of components, together with Waldencast’s, Obagi Medical’s or Novaestiq’s lack of ability to implement their enterprise plans, and (viii) the flexibility to implement Waldencast’s strategic initiatives and proceed to innovate Obagi Medical’s current merchandise and anticipate and reply to market tendencies and adjustments in shopper preferences. The foregoing listing of things isn’t exhaustive. You must fastidiously think about the foregoing components and the opposite dangers and uncertainties described within the “Danger Components” part of Waldencast’s Annual Report on Kind 20-F for the 12 months ended December 31, 2024, filed with the SEC on March 20, 2025, or in different paperwork which may be filed or furnished by Waldencast every so often with the SEC. These filings determine and handle different vital dangers and uncertainties that might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Ahead-looking statements converse solely as of the date they’re made. Readers are cautioned to not put undue reliance on forward-looking statements, and Waldencast assumes no obligation and don’t intend to replace or revise these forward-looking statements, whether or not because of new info, future occasions, or in any other case.

Contacts

Buyers
ICR
WaldencastIR@icrinc.com

Media
ICR
WaldencastPR@icrinc.com